Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047

Anti-Cancer Drugs

Volumn 21, Issue 10, 2010, Pages 897-906

  Cirenajwis, Helena ^a   Smiljanic, Sandra ^a   Honeth, Gabriella ^b   Hegardt, Cecilia ^b   Marton, Laurence J ^c   Oredssona, Stina M ^a  

^a LUND UNIVERSITY   (Sweden)

^b Clinical Sciences ^*  (Sweden)

^c Progen Pharmaceuticals   (United States)

Author keywords

7 dehydrospermine; 1N,12N bis(ethyl) cis 6; Breast cancer stem cells; Mesenchymal to epithelial transition; Polyamine analogue

Indexed keywords

[1 N,12 N]BIS(ETHYL) 6,7 DEHYDROSPERMINE; ANTINEOPLASTIC AGENT; CD24 ANTIGEN; CD44V ANTIGEN; CYTOKERATIN 18; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; PG 11047; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER STEM CELL; CELL DEATH; CELL DIFFERENTIATION; CELL MOTILITY; CELL POPULATION; CELL RENEWAL; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MESENCHYME CELL; PHENOTYPE; POLYAMINE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD24; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; EFLORNITHINE; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPERMINE;

EID: 78650045248     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833f2f77     Document Type: Article

References (53)

1. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Cacerescortes J, et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994; 367:645-648.
2. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445:111-115.
3. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445:106-110.
4. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65:10946-10951.
5. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44( + )CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Brit J Cancer 2008; 98:756-765.
6. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63:5821-5828.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983-3988. (Pubitemid 36418143)
8. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10:R1-R13.
9. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65:5506-5511.
10. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+ /CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006; 8:R59. doi:10.1186/bcr1610. (Pubitemid 44804002)
11. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44(+ )/CD24(-/low) cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005; 11:1154-1159.
12. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006; 12:5615-5621.
13. Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C, et al. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 2008; 122:298-304.
14. Crowe DL, Ohannessian A. Recruitment of focal adhesion kinase and paxillin to beta1 integrin promotes cancer cell migration via mitogen activated protein kinase activation. BMC Cancer 2004; 4:18.
15. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1:555-567.
16. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69:1302-1313.
17. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou JJ, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2( + ) and ABCG2(-) cancer cells are similarly tumorigenic. Cancer Res 2005; 65:6207-6219.
18. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139:871-890.
19. Hay ED. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 2005; 233:706-720.
20. Eastham AM, Spencer H, Soncin F, Ritson S, Merry CLR, Stern PL, et al. Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res 2007; 67:11254-11262.
21. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-715.
22. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLos One 2008; 3:e2888. doi:10.1371/journal.pone.0002888.
23. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, Van Roy F, Lee-Kwon W, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003; 63:2172-2178.
24. Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27:6120-6130.
25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL. Human-breast cancer-correlation of relapse and survival with amplification of the HER-2 neu oncogene. Science 1987; 235:177-182.
26. Miller KD. The role of ErbB inhibitors in trastuzumab resistance. Oncologist 2004; 9 (Suppl 3):16-19.
27. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/ CD44( + ) breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98:1777-1785.
28. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009; 15:4234-4241.
29. Creighton CJ, Li XX, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009; 106:13820-13825.
30. Casero RA, Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007; 6:373-390.
31. Reddy VK, Valasinas A, Sarkar A, Basu HS, Marton LJ, Frydman B. Conformationally restricted analogues of N-1,N-12-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. J Med Chem 1998; 41:4723-4732.
32. Kuo WL, Das D, Ziyad S, Bhattacharya S, Gibb WJ, Heiser LM, et al. A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med 2009; 7:77.
33. Holst CM, Frydman B, Marton LJ, Oredsson SM. Differential polyamine analogue effects in four human breast cancer cell lines. Toxicol 2006; 223:71-81.
34. Hacker A, Marton LJ, Sobolewski M, Casero RA. In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells. Cancer Chemother Pharmacol 2008; 63:45-53.
35. Dredge K, Kink JA, Johnson RM, Bytheway I, Marton LJ. The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer. Cancer Chemother Pharmacol 2009; 65:191-195.
36. Metcalf BW, Bey P, Danzin C, Jung MJ, Casara P, Vevert JP. Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E C 4.1.1.17) by substrate and product analogs. J Am Chem Soc 1978; 100:2551-2553.
37. Shantz LM, Levin VA. Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential. Amino Acids 2007; 33:213-223.
38. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, doubleblind trial. Cancer Prev Res (Phila Pa) 2008; 1:32-38.
39. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17:1253-1270.
40. Molder A, Sebesta M, Gustafsson M, Gisselson L, Wingren AG, Alm K. Non-invasive, label-free cell counting and quantitative analysis of adherent cells using digital holography. J Microsc 2008; 232:240-247.
41. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/betacatenin signaling. PLoS Biol 2009; 7:e1000121. doi:10.1371/ journal.pbio.1000121.
42. Gupta PB, Onder TT, Jiang GZ, Tao K, Kuperwasser C,Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138:645-659.
43. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004; 3:1585-1592.
44. Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 2009; 100:1062-1068.
45. Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB,Woster PM, et al. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A 2007; 104:8023-8028.
46. Ghatak S, Misra S, Toole BP. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 2002; 277:38013-38020.
47. Kurrey NK, K A, Bapat SA. Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol 2005; 97:155-165.
48. Woelfle U, Sauter G, Santjer S, Brakenhoff R, Pantel K. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res 2004; 10:2670-2674.
49. Oliveira LR, Jeffrey SS, Ribeiro-Silva A. Stem cells in human breast cancer. Histol Histopathol 2010; 25:371-385.
50. Wang HS, Hung Y, Su CH, Peng ST, Guo YJ, Lai MC, et al. CD44 cross-linking induces integrin-mediated adhesion, and transendothelial migration in breast cancer cell line by up-regulation of LFA-1 (alpha L beta 2) and VLA-4 (alpha 4 beta 1). Exp Cell Res 2005; 304:116-126.
51. Liang M, Ekblad E, Hellstrand P, Nilsson BO. Polyamine synthesis inhibition attenuates vascular smooth muscle cell migration. J Vasc Res 2004; 41:141-147.
52. Ray RM, Vaidya RJ, Johnson LR. MEK/ERK regulates adherens junctions and migration through Rac1. Cell Motil Cytoskeleton 2007; 64:143-156.
53. McCormack SA, Viar MJ, Johnson LR. Migration of Iec-6 cells-a model for mucosal healing. Am J Physiol 1992; 263:G426-G435.